St. Jude Warning Letter Updates: CRM Facility Reinspected; Neuro Plant Awaits FDA Visit
This article was originally published in The Gray Sheet
Executive Summary
St. Jude updated the status of its efforts to resolve FDA warnings letters linked to its cardiac rhythm management and neuromodulation divisions during its first-quarter earnings call on April 16.